Open Access

Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases

Maja Sljivic
Maja Sljivic
, 
Masa Sever
Masa Sever
, 
Janja Ocvirk
Janja Ocvirk
, 
Tanja Mesti
Tanja Mesti
, 
Erik Brecelj
Erik Brecelj
 and 
Peter Popovic
Peter Popovic
   | Mar 30, 2024
Radiology and Oncology's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: Research Article
Published Online: Mar 30, 2024
Page range: -
Received: Dec 13, 2023
Accepted: Mar 06, 2024
DOI: https://doi.org/10.2478/raon-2024-0023
Keywords
© 2024 Maja Sljivic et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

FIGURE 1.

Overall survival (OS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.
Overall survival (OS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.

FIGURE 2.

Progression-free survival (PFS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.
Progression-free survival (PFS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.

FIGURE 3.

Overall survival (OS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.
Overall survival (OS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.

FIGURE 4.

Progression-free survival (PFS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.
Progression-free survival (PFS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.

Patient demographics and clinicopathological features

Age in years
  Median (range) 68 (34–85)
Sex n (%)
  Male 22 (73)
  Female 8 (27)
Primary tumour
  Colon 16 (53)
  Rectum 14 (47)
ECOG performance status
  0 18 (60)
  1 9 (30)
  2 3 (10)
Liver metastases
  Unilobar 17 (57)
  Bilobar 13 (43)
  ≤ 4 lesions 19 (63)
  > 4 lesions 11 (37)
Previous chemotherapy
  Yes 17 (57)
  No 13 (43)

Univariate analysis – influence of probable prognostic factors on overall survival

Characteristics n (%) OS 95 % CI p-value
Age ≤ 65 years 11 (37) 15.2 8.5–21.8 0.284
Age > 65 years 19 (63) 21.6 4.7–38.4.
Colon 16 (53) 23.7 16.8–30.5 0.145
Rectum 14 (47) 14.1 6.8–21.4
ECOG 0 18 (60) 19.8 11.3–28.4 0.805
ECOG 1 or 2 12 (40) 17.4 10.0–29.7
Previous chemotherapy 17 (57) 17.4 11.0–23.7 0.472
No previous chemotherapy 13 (43) 21.6 3.8–39.4
Unilobar disease 17 (57) 23.5 7.4–39.6 0.106
Bilobar disease 13 (43) 15.2 1.9–28.4
≤ 4 liver lesions 19 (63) 23.5 15.5–31.5 0.002
> 4 liver lesions 11 (37) 10.8 0.3–21.3
CEA ≤ 5 µg/L before the first DEBIRI TACE 5 (27) 17.4 5.9–28.9 0.591
CEA > 5 µg/L before the first DEBIRI TACE 22 (73) 15.2 9.2–21.1
Increase of serum CEA after first DEBIRI TACE 10 (33) 14.1 7.3–20.9 0.037
Decrease of serum CEA after first DEBIRI TACE 12 (40) 24.7 7.0–42.4
CEA stayed the same 1 (3) 25.5
CA 19-9 ≤ 37 kU/L before first DEBIRI TACE 16 (53) 15.2 10.1–20.2 0.393
CA 19-9 > 37 kU/L before first DEBIRI TACE 11 (47) 17.4 0.5–34.2
Increase of serum CA 19-9 after first DEBIRI TACE 11 (48) 15.2 11.7–18.7 0.583
Decrease of serum CA 19-9 after first DEBIRI TACE 10 (43) 19.8 0.0–44.9
CA 19-9 stayed the same 2 (9) 7.4
eISSN:
1581-3207
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed